Table of Contents Title of Each Class Trading symbol Name of Exchange on which registered Common Stock, par value $0.0001 per share (1) (1) Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share (1) (1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41567 ProSomnus, Inc. (Exact name of registrant as specified in its charter) DE 88-2978216 (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 ProSomnus, Inc. (Exact name of registrant as specified in its charter) | --- | --- | --- | |-----------------------------------------|-------------------------------------------------------------------|-----------------------| | Delaware | 001-41567 | 88-2978216 | | (State or other ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 18-K R PROSOMNUS, INC. (Exact name of registrant as specified in its charter) Delaware 88-2978216 (State of Other Jurisdiction of incorporation or Organization) (I.R.S. Employer Identification No.) 5675 Gibraltar Drive, Pleasanton, CA 94588 (Address of principal executive offices) (Zip code) Registrant's telephone number, including area code: (844) 537-5337 Securities registered pursuant to Section 12(b) of the Ac ...

Exhibit 99.1 ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results PLEASANTON, Calif., (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth quarter and year ended December 31, 2023. Recent Business Highlights · Generated record revenues of $7.8 million for the fourth quarter and $27.7 million for the fiscal year 2023, a 35% increase compared to $5.8 millio ...

PLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today it has postponed the release of its 2023 fourth quarter and full year financial results and the related investor conference call. The rescheduled call will be held after market close on Tuesday, March 26, 2024 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Registration and dial-in information can be found on the investor relat ...

PLEASANTON, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today that the United States Food and Drug Administration (the "FDA") has accepted, and is in the process of reviewing, the Company's premarket notification for its ProSomnus® EVO® precision medical device for the treatment of patients with severe obstructive sleep apnea. "The acceptance of our 510(k) submission for substantive review repr ...

PLEASANTON, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that the company is well-positioned to support patients with OSA and sleep physicians who can no longer access discontinued OSA devices. Earlier in January, Philips Respironics announced the discontinuation of many devices used for the treatment and diagnosis of sleep apnea, including CPAP systems. This discontinuation follows several U.S. ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading symbol Name of Exchange on which registered Common Stock, par value $0.0001 per share OSA The Nasdaq Global Market Warrants, each whole warrant exercisable for one share of Common Stock for $11.50 per share OSAAW The Nasdaq Global Market UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN ...

Table of Contents OSAAW The Nasdaq Stock Market LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41567 ProSomnus, Inc. (Exact name of registrant as specified in its charter) ...